UNSPSC 51283215: Relomycin

This classification denotes a macrolide antibiotic with the molecular formula C46H79NO17, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier E70CPL81IY. The term RELOMYCIN is an International Non-Proprietary Name or INN. RELOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CCO)C)C)COC4C(C(C(C(O4)C)O)OC)OC.

UNSPSC 51283215 Relomycin is a Commodity code that does not match the work described in recent state and local solicitations posted under this classification. The four opportunities identified—ranging from naloxone and drug deactivation systems procurement in Florida, to direct-to-manufacturer pharmacy initiatives in Texas, to medical and first aid supplies in Tampa, to generic pharmaceuticals through a multistate cooperative in Minnesota—involve naloxone, over-the-counter products, emergency medical supplies, and generic pharmaceuticals, none of which align with relomycin (a specific pharmaceutical agent). State and local procurement systems appear to have tagged these opportunities with this code despite the absence of relomycin-specific demand signals in the market.

The code shows little relevant recent activity. No issuing body is soliciting relomycin specifically, and the geographic distribution of recent opportunities—Florida, Texas, Minnesota, and Oregon through cooperative purchasing—reflects broader pharmaceutical and medical supply procurement patterns unrelated to this particular commodity. Buyers seeking to pursue opportunities under this code should verify the actual product requirements in any solicitation tagged with UNSPSC 51283215, as the tagging does not appear to reflect current state and local purchasing activity for relomycin itself.